Federal Register / Vol. 61, No. 86 / Thursday, May 2, 1996 / Notices 19629

Health Care Financing Administration

(HCFA), Department of Health and

Human Services, is publishing the

following summary of proposed

collections for public comment.

Interested persons are invited to send

comments regarding the burden

estimate or any other aspect of this

collection of information, including any

of the following subjects: (1) The

necessity and utility of the proposed

information collection for the proper

performance of the agency’s functions;

(2) the accuracy of the estimated

burden; (3) ways to enhance the quality,

utility, and clarity of the information to

be collected; and (4) the use of

automated collection techniques or

other forms of information technology to

minimize the information collection

burden.

Type of Information Collection

Request: Reinstatement, without change,

of a previously approved collection for

which approval has expired; Title of

Information Collection: Information

Collection Requirements in BPD–458–F,

Section 411.408(d)(2) and (f); Form No.:

HCFA–R–131; Use: Physicians who do

not accept assignment may bill a patient

for services denied by Medicare as ‘‘not

reasonable and necessary,’’ if they

informed the patient, prior to furnishing

the services, that Medicare was likely to

deny part B payments for services and

the patient, after being so informed,

agrees to pay for the services.

Frequency: On occasion; Affected

Public: Individuals or Households;

Number of Respondents: 237,322; Total

Annual Responses: 925,904; Total

Annual Hours Requested: 115,738.

To request copies of the proposed

paperwork collections referenced above,

call the Reports Clearance Office on

(410) 786–1326. Written comments and

recommendations for the proposed

information collections should be sent

within 60 days of this notice directly to

the HCFA Paperwork Clearance Officer

designated at the following address:

HCFA, Office of Financial and Human

Resources Management Planning and

Analysis Staff, Attention: Louis Blank,

Room C2–26–17, 7500 Security

Boulevard, Baltimore, Maryland 21244–

1850.

Dated: April 24, 1996.

Kathleen B. Larson,

Director, Management Planning and Analysis

Staff, Office of Financial and Human

Resources.

[FR Doc. 96–10864 Filed 5–1–96; 8:45 am]

BILLING CODE 4120–03–P

Substance Abuse and Mental Health

Services Administration

Current List of Laboratories Which

Meet Minimum Standards To Engage in

Urine Drug Testing for Federal

Agencies, and Laboratories That Have

Withdrawn From the Program

AGENCY: Substance Abuse and Mental

Health Services Administration, HHS

(Formerly: National Institute on Drug

Abuse, ADAMHA, HHS).

ACTION: Notice.

SUMMARY: The Department of Health and

Human Services notifies Federal

agencies of the laboratories currently

certified to meet standards of Subpart C

of Mandatory Guidelines for Federal

Workplace Drug Testing Programs (59

FR 29916, 29925). A similar notice

listing all currently certified laboratories

will be published during the first week

of each month, and updated to include

laboratories which subsequently apply

for and complete the certification

process. If any listed laboratory’s

certification is totally suspended or

revoked, the laboratory will be omitted

from updated lists until such time as it

is restored to full certification under the

Guidelines.

If any laboratory has withdrawn from

the National Laboratory Certification

Program during the past month, it will

be identified as such at the end of the

current list of certified laboratories, and

will be omitted from the monthly listing

thereafter.

FOR FURTHER INFORMATION CONTACT: Mrs.

Giselle Hersh, Division of Workplace

Programs, Room 13A–54, 5600 Fishers

Lane, Rockville, Maryland 20857; Tel.:

(301) 443–6014.

SUPPLEMENTARY INFORMATION:

Mandatory Guidelines for Federal

Workplace Drug Testing were developed

in accordance with Executive Order

12564 and section 503 of Pub. L. 100–

71. Subpart C of the Guidelines,

‘‘Certification of Laboratories Engaged

in Urine Drug Testing for Federal

Agencies,’’ sets strict standards which

laboratories must meet in order to

conduct urine drug testing for Federal

agencies. To become certified an

applicant laboratory must undergo three

rounds of performance testing plus an

on-site inspection. To maintain that

certification a laboratory must

participate in a quarterly performance

testing program plus periodic, on-site

inspections.

Laboratories which claim to be in the

applicant stage of certification are not to

be considered as meeting the minimum

requirements expressed in the HHS

Guidelines. A laboratory must have its

letter of certification from SAMHSA,

HHS (formerly: HHS/NIDA) which

attests that it has met minimum

standards.

In accordance with Subpart C of the

Guidelines, the following laboratories

meet the minimum standards set forth

in the Guidelines:

Aegis Analytical Laboratories, Inc. 624

Grassmere Park Rd., Suite 21,

Nashville, TN 37211, 615–331–5300

Alabama Reference Laboratories, Inc.,

543 South Hull St., Montgomery, AL

36103, 800–541–4931/205–263–5745

American Medical Laboratories, Inc.,

14225 Newbrook Dr., Chantilly, VA

22021, 703–802–6900

Associated Pathologists Laboratories,

Inc., 4230 South Burnham Ave., Suite

250, Las Vegas, NV 89119–5412, 702–

733–7866

Associated Regional and University

Pathologists, Inc. (ARUP), 500 Chipeta

Way, Salt Lake City, UT 84108, 801–

583–2787

Baptist Medical Center—Toxicology

Laboratory, 9601 I–630, Exit 7, Little

Rock, AR 72205–7299, 501–227–2783

(formerly: Forensic Toxicology

Laboratory Baptist Medical Center)

Bayshore Clinical Laboratory, 4555 W.

Schroeder Dr., Brown Deer, WI 53223,

414–355–4444/800–877–7016

Cedars Medical Center, Department of

Pathology, 1400 Northwest 12th Ave.,

Miami, FL 33136, 305–325–5810

Centinela Hospital Airport Toxicology

Laboratory, 9601 S. Sepulveda Blvd.

Los Angeles, CA 90045, 310–215–

6020

Clinical Reference Lab, 11850 West 85th

St., Lenexa, KS 66214, 800–445–6917

CompuChem Laboratories, Inc., 3308

Chapel Hill/Nelson Hwy., Research

Triangle Park, NC 27709, 919–549–

8263/800–833–3984 (Formerly:

CompuChem Laboratories, Inc., A

Subsidiary of Roche Biomedical

Laboratory, Roche CompuChem

Laboratories, Inc., A Member of the

Roche Group)

CORNING Clinical Laboratories, 4771

Regent Blvd., Irving, TX 75063, 800–

526–0947 (formerly: Damon Clinical

Laboratories, Damon/MetPath)

CORNING Clinical Laboratories, 875

Greentree Rd., 4 Parkway Ctr.,

Pittsburgh, PA 15220–3610, 800–284–

7515 (formerly: Med-Chek

Laboratories, Inc., Med-Chek/Damon,

MetPath Laboratories)

CORNING Clinical Laboratories, 24451

Telegraph Rd., Southfield, MI 48034,

800–444–0106, ext. 650 (formerly:

HealthCare/Preferred Laboratories,

Health Care/MetPath)

CORNING Clinical Laboratories Inc.,

1355 Mittel Blvd., Wood Dale, IL
19630 Federal Register / Vol. 61, No. 86 / Thursday, May 2, 1996 / Notices

60191, 708–595–3888 (formerly:

MetPath, Inc., CORNING MetPath

Clinical Laboratories)

CORNING Clinical Laboratories, South

Central Divison, 2320 Schuetz Rd., St.

Louis, MO 63146, 800–288–7293

(formerly: Metropolitan Reference

Laboratories, Inc.)

CORNING Clinical Laboratory, One

Malcolm Ave., Teterboro, NJ 07608,

201–393–5000 (formerly: MetPath,

Inc., CORNING MetPath Clinical

Laboratories)

CORNING National Center for Forensic

Science, 1901 Sulphur Spring Rd.,

Baltimore, MD 21227, 410–536–1485

(formerly: Maryland Medical

Laboratory, Inc., National Center for

Forensic Science)

CORNING Nichols Institute, 7470–A

Mission Valley Rd., San Diego, CA

92108–4406, 800–446–4728/619–686–

3200 (formerly: Nichols Institute,

Nichols Institute Substance Abuse

Testing (NISAT))

Cox Medical Centers, Department of

Toxicology, 1423 North Jefferson

Ave., Springfield, MO 65802, 800–

876–3652/417–836–3093

Dept. of the Navy, Navy Drug Screening

Laboratory, Great Lakes, IL, Building

38–H, Great Lakes, IL 60088–5223,

708–688–2045/708–688–4171

Diagnostic Services Inc., dba DSI, 4048

Evans Ave., Suite 301, Fort Myers, FL

33901, 813–936–5446/800–735–5416

Doctors Laboratory, Inc., P.O. Box 2658,

2906 Julia Dr., Valdosta, GA 31604,

912–244–4468

Drs. Weber, Palmer, Macy, Chartered,

338 N. Front St., Salina, KS 67401,

913–823–9246

DrugProof, Division of Dynacare/

Laboratory of Pathology, LLC, 1229

Madison St., Suite 500, Nordstrom

Medical Tower, Seattle, WA 98104,

800–898–0180/206–386–2672

(formerly: Laboratory of Pathology of

Seattle, Inc., DrugProof, Division of

Laboratory of Pathology of Seattle,

Inc.)

DrugScan, Inc., P.O. Box 2969, 1119

Mearns Rd., Warminster, PA 18974,

215–674–9310

ElSohly Laboratories, Inc., 5 Industrial

Park Dr., Oxford, MS 38655, 601–236–

2609

General Medical Laboratories, 36 South

Brooks St., Madison, WI 53715, 608–

267–6267

Harrison Laboratories, Inc., 9930 W.

Highway 80, Midland, TX 79706,

800–725–3784/915–563–3300

(formerly: Harrison & Associates

Forensic Laboratories)

Jewish Hospital of Cincinnati, Inc. 3200

Burnet Ave., Cincinnati, OH 45229,

513–569–2051

LabOne, Inc., 8915 Lenexa Dr., Overland

Park, Kansas 66214, 913–888–3927

(formerly: Center for Laboratory

Services, a Division of LabOne, Inc.)

Laboratory Corporation of America,

13900 Park Center Rd., Herndon, VA

22071, 703–742–3100 (Formerly:

National Health Laboratories

Incorporated)

Laboratory Corporation of America,

21903 68th Ave. South, Kent, WA

98032, 206–395–4000 (Formerly:

Regional Toxicology Services)

Laboratory Corporation of America

Holdings, 1120 Stateline Rd.,

Southaven, MS 38671, 601–342–1286

(Formerly: Roche Biomedical

Laboratories, Inc.)

Laboratory Corporation of America

Holdings, 69 First Ave., Raritan, NJ

08869, 800–437–4986 (Formerly:

Roche Biomedical Laboratories, Inc.)

Laboratory Specialists, Inc., 113 Jarrell

Dr., Belle Chasse, LA 70037, 504–

392–7961

Marshfield Laboratories, 1000 North

Oak Ave., Marshfield, WI 54449, 715–

389–3734/800–222–5835

MedExpress/National Laboratory

Center, 4022 Willow Lake Blvd.,

Memphis, TN 38175, 901–795–1515

Medical College Hospitals Toxicology

Laboratory, Department of Pathology,

3000 Arlington Ave., Toledo, OH

43699–0008, 419–381–5213

Medlab Clinical Testing, Inc., 212

Cherry Lane, New Castle, DE 19720,

302–655–5227

MedTox Laboratories, Inc., 402 W.

County Rd. D, St. Paul, MN 55112,

800–832–3244/612–636–7466

Methodist Hospital of Indiana, Inc.,

Department of Pathology and

Laboratory Medicine, 1701 N. Senate

Blvd., Indianapolis, IN 46202, 317–

929–3587

Methodist Medical Center Toxicology

Laboratory, 221 N.E. Glen Oak Ave.,

Peoria, IL 61636, 800–752–1835/309–

671–5199

MetroLab-Legacy Laboratory Services,

235 N. Graham St., Portland, OR

97227, 503–413–4512, 800–237–

7808(x4512)

National Toxicology Laboratories, Inc.,

1100 California Ave., Bakersfield, CA

93304, 805–322–4250

Northwest Toxicology, Inc., 1141 E.

3900 South, Salt Lake City, UT 84124,

800–322–3361

Oregon Medical Laboratories, P.O. Box

972, 722 East 11th Ave., Eugene, OR

97440–0972, 503–687–2134

Pathology Associates Medical

Laboratories, East 11604 Indiana,

Spokane, WA 99206, 509–926–2400

PharmChem Laboratories, Inc., 1505–A

O’Brien Dr., Menlo Park, CA 94025,

415–328–6200/800–446–5177

PharmChem Laboratories, Inc., Texas

Division, 7606 Pebble Dr., Fort Worth,

TX 76118, 817–595–0294 (formerly:

Harris Medical Laboratory)

Physicians Reference Laboratory, 7800

West 110th St., Overland Park, KS

66210, 913–338–4070/800–821–3627

Poisonlab, Inc., 7272 Clairemont Mesa

Rd., San Diego, CA 92111, 619–279–

2600/800–882–7272

Premier Analytical Laboratories, 15201

I–10 East, Suite 125, Channelview, TX

77530, 713–457–3784 (formerly: Drug

Labs of Texas)

Presbyterian Laboratory Services, 1851

East Third Street, Charlotte, NC

28204, 800–473–6640

Puckett Laboratory, 4200 Mamie St.,

Hattiesburgh, MS 39402, 601–264–

3856/800–844–8378

Scientific Testing Laboratories, Inc., 463

Southlake Blvd., Richmond, VA

23236, 804–378–9130

Scott & White Drug Testing Laboratory,

600 S. 25th St., Temple, TX 76504,

800–749–3788

S.E.D. Medical Laboratories, 500 Walter

NE, Suite 500, Albuquerque, NM

87102, 505–244–8800, 800–999–LABS

Sierra Nevada Laboratories, Inc., 888

Willow St., Reno, NV 89502, 800–

648–5472

SmithKline Beecham Clinical

Laboratories, 7600 Tyrone Ave., Van

Nuys, CA 91045, 818–989–2520

SmithKline Beecham Clinical

Laboratories, 801 East Dixie Ave.,

Leesburg, FL 34748, 904–787–9006

(formerly: Doctors & Physicians

Laboratory)

SmithKline Beecham Clinical

Laboratories, 3175 Presidential Dr.,

Atlanta, GA 30340, 770–452–1590

(formerly: SmithKline Bio-Science

Laboratories)

SmithKline Beecham Clinical

Laboratories, 506 E. State Pkwy.,

Schaumburg, IL 60173, 708–885–2010

(formerly: International Toxicology

Laboratories)

SmithKline Beecham Clinical

Laboratories, 400 Egypt Rd.,

Norristown, PA 19403, 800–523–5447

(formerly: SmithKline Bio-Science

Laboratories)

SmithKline Beecham Clinical

Laboratories, 8000 Sovereign Row,

Dallas, TX 75247, 214–638–1301

(formerly: SmithKline Bio-Science

Laboratories)

SmithKline Beecham Clinical

Laboratories, 1737 Airport Way

South, Suite 200, Seattle, WA 98134,

206–623–8100

South Bend Medical Foundation, Inc.,

530 N. Lafayette Blvd., South Bend,

IN 46601, 219–234–4176

Southwest Laboratories, 2727 W.

Baseline Rd., Suite 6, Tempe, AZ

85283, 602–438–8507

St. Anthony Hospital (Toxicology

Laboratory), P.O. Box 205, 1000 N.
Federal Register / Vol. 61, No. 86 / Thursday, May 2, 1996 / Notices 19631

Lee St., Oklahoma City, OK 73102,

405–272–7052

Toxicology & Drug Monitoring

Laboratory, University of Missouri

Hospital & Clinics, 2703 Clark Lane,

Suite B, Lower Level, Columbia, MO

65202, 314–882–1273

Toxicology Testing Service, Inc., 5426

N.W. 79th Ave., Miami, FL 33166,

305–593–2260

TOXWORX Laboratories, Inc., 6160

Variel Ave., Woodland Hills, CA

91367, 818–226–4373 (formerly:

Laboratory Specialists, Inc.; Abused

Drug Laboratories; MedTox BioAnalytical, a Division of MedTox

Laboratories, Inc.)

UNILAB, 18408 Oxnard St., Tarzana,

CA 91356, 800–492–0800/818–343–

8191 (formerly: MetWest-BPL

Toxicology Laboratory)

The following laboratory withdrew

from the National Laboratory

Certification Program on April 15, 1996:

PDLA, Inc. (Princeton), 100 Corporate

Court, So. Plainfield, NJ 07080, 908–

769–8500/800–237–7352

The following laboratory withdrew

from the National Laboratory

Certification Program on April 26, 1996:

Holmes Regional Medical Center

Toxicology Laboratory, 5200 Babcock

St., N.E., Suite 107, Palm Bay, FL

32905, 407–726–9920

Richard Kopanda,

Executive Officer, Substance Abuse and

Mental Health Services Administration.

[FR Doc. 96–10846 Filed 5–1–96; 8:45 am]

BILLING CODE 4160–20–P

DEPARTMENT OF HOUSING AND

URBAN DEVELOPMENT

[Docket No. FR–4051–N–01]

Office of the Assistant Secretary for

Housing—Federal Housing

Commissioner; Mortgagee Review

Board Administrative Actions

AGENCY: Office of the Assistant

Secretary for Housing—Federal Housing

Commissioner, HUD.

ACTION: Notice.

SUMMARY: In compliance with Section

202(c) of the National Housing Act,

notice is hereby given of the cause and

description of administrative actions

taken by HUD’s Mortgagee Review

Board against HUD-approved

mortgagees.

FOR FURTHER INFORMATION CONTACT:

William Heyman, Director, Office of

Lender Activities and Program

Compliance, 451 Seventh Street, S.W.,

Washington, D.C. 20410, telephone

(202) 708–1515 (this is not a toll-free

number). Hearing- or speech-impaired

individuals may access this number by

calling the Federal Information Relay

Service TTY at 1–800–877–8339.

SUPPLEMENTARY INFORMATION: Section

202(c)(5) of the National Housing Act

(added by Section 142 of the

Department of Housing and Urban

Development Reform Act of 1989

(Pub.L. 101–235), approved December

15, 1989, requires that HUD ‘‘publish in

the Federal Register a description of

and the cause for administrative action

against a HUD-approved mortgagee’’ by

the Department’s Mortgagee Review

Board. In compliance with the

requirements of Section 202(c)(5), notice

is hereby given of administrative actions

that have been taken by the Mortgagee

Review Board from October 1, 1995

through March 31, l996.

1. Associate Trust Financial Services;

Camp Springs, Maryland

Action: Proposed withdrawal of HUDFHA mortgagee approval.

Cause: Alleged submission of false

information to the Department in

connection with three HUD-FHA

insured mortgage loan transactions.

2. Directors Mortgage Loan

Corporation/Norwest Mortgage, Inc.;

Des Moines, Iowa

Action: Settlement agreement that

includes indemnification to the

Department for any claim losses in

connection with 56 improperly

originated FHA insured mortgages;

payment of a civil money penalty in the

amount of $56,000; and an independent

CPA review in the future to determine

compliance with the HUD-FHA Section

203(k) program requirements.

Cause: A HUD monitoring review that

disclosed violations of HUD-FHA

Section 203(k) program requirements by

Directors Mortgage Loan Corporation,

which was subsequently purchased by

Norwest Mortgage, Inc. The violations

included: calculating maximum

mortgage amounts using a purchase

contract that did not reflect the true

purchase price; violating the seven unit

limitation; improperly adding mortgage

payments in the property rehabilitation

cost; failure to perform field reviews of

appraisals involving investor loans;

permitting the seller to loan the required

investment for the benefit of the

mortgagor; miscalculating maximum

mortgage amounts by failing to deduct

seller concessions from the purchase

price; and permitting loans to close that

contained alleged false statements.

3. The Money Store; Sacramento,

California

Action: Settlement agreement that

includes: cancellation of HUD-FHA

insurance in connection with six

improperly originated Title I loans;

payment to the Department in the

amount of $35,000; and a future review

by a CPA or other independent party to

determine compliance with HUD-FHA

Title I program requirements.

Cause: A HUD monitoring review that

disclosed violations of HUD-FHA Title

I property improvement loan program

requirements that included: failure to

properly service Title I loans; failure to

timely submit insurance claims; and

failure to timely report the sale of Title

I notes and transfers of insurance

reserves.

4. Empire Funding Corporation; Austin,

Texas

Action: Settlement agreement that

includes: cancellation of HUD-FHA

insurance in connection with seven

improperly originated Title I loans;

indemnification for the Department’s

claim loss on one improperly originated

Title I loan; payment of a civil money

penalty in the amount of $13,000; and

corrective action to assure compliance

with HUD-FHA requirements.

Cause: A HUD monitoring review that

disclosed violations of HUD-FHA Title

I property improvement loan program

requirements that included: accepting

falsified completion certificates; alleged

falsified lender inspection reports;

failure to resolve borrower complaints;

permitting dealers to participate without

regard to performance; and failure to

report dealer irregularities.

5. TMI Financial, Inc.; Austin, Texas

Action: Settlement agreement that

includes a voluntary exclusion from

participation in the HUD-FHA Title I

property improvement loan program for

a period of one year and a civil money

penalty of $132,000.

Cause: A HUD monitoring review that

disclosed violations of HUD-FHA Title

I property improvement loan program

requirements that included: submitting

alleged false insurance claims; accepting

falsified completion certificates; alleged

falsified lender inspection reports;

failure to resolve borrower complaints;

and failure to report dealer

irregularities.

6. New England Mortgage Brokers, Inc.;

North Andover, Massachusetts

Action: Settlement agreement that

includes: payment to the Department of

a civil money penalty in the amount of

$3,000; corrective action to assure

compliance with HUD–FHA